ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
biospace
April 10, 2018?AbbVie?(NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-COMPARE clinical trial -
Upadacitinib receives breakthrough therapy designation for atopic dermatitis
europeanpharmaceuticalreview
January 10, 2018Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018… -
AbbVie Scores Key Trial Win for RA Drug With One Fatal Event Reported
biospace
December 21, 2017AbbVie’s investigational JAK1-inhibitor?upadacitinib yielded positive?top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. But the drug shows that it is still plagued by some safety concerns. ?
Pharma Sources Insight January 2025
